

**II. REMARKS**

The Office Action dated May 12, 2008, has been received and carefully noted. The amendments made herein and the following remarks are submitted as a full and complete response thereto.

By this Amendment, claims 1, 5, 7, 8, 9, and 12-20 are amended, and claim 2 is canceled. Applicants submit that support for the amendment can be found in the specification and claims as originally filed. For example, claim 1 has been amended to incorporate the limitation of canceled claim 2. Claims 19 has been amended to conform to U.S. patent practice, and claims 5, 7, 8, 9, and 12-20 have been amended to correct informalities and/or remove multiple dependency. Applicants submit that no new matter has been added and respectfully request reconsideration and withdrawal of the Restriction Requirement.

In response to the Restriction Requirement, Applicants elect Group I, with traverse. Group I is claims 1-19, drawn to a drug delivery composition comprising 2-[2-(nitroxy)ethoxy]ethyl {2-[(2,6-dichlorphenyl)amino]phenyl} acetate in melted form absorbed/adsorbed onto/into particles.

This election is made with traverse, and without prejudice to or disclaimer of the other claims or inventions disclosed. Applicants reserve the right to file divisional applications directed to the non-elected subject matter.

Traversal is on the grounds that the burden on the Patent Office to consider all of the groups of claims together is less than the burden on Applicants/the public to prosecute/search the applications/patents separately.


In view of the Applicants' above election, Applicants respectfully submit that the Restriction Requirement has been satisfied. Applicants submit that claims 1-19 read on the elected invention. Accordingly, Applicants respectfully request examination of claims 1-19 on the merits.

**III. CONCLUSION**

Applicants respectfully submit that this application is in condition for allowance and such action is earnestly solicited. If the Examiner believes that anything further is desirable in order to place this application in even better condition for allowance, the Examiner is invited to contact Applicants' undersigned representative at the telephone number listed below to schedule a personal or telephone interview to discuss any remaining issues.

In the event that this paper is not considered to be timely filed, an appropriate extension of time is requested. Any fees for such an extension, together with any additional fees that may be due with respect to this paper, may be charged to Deposit Account No. 01-2300, referencing Attorney Docket Number 026220.00071.

Respectfully submitted,



Yeleen Y. Kim  
Registration Number 60,088

Customer Number 004372  
AREN'T FOX LLP  
1050 Connecticut Avenue, NW, Suite 400  
Washington, DC 20036-5339  
Telephone: 202-857-6000  
Fax: 202-857-6395